ReviewMicrosystems & nanoengineering2026
Advancing non-faradaic impedance biosensors: sensitivity enhancement strategies using microfluidics, multiscale labeling, and CMOS technology.
Review in Microsystems & nanoengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Impedance biosensors represent a critical technology for next-generation diagnostics, offering label-free detection with inherent compatibility for miniaturization. Among these, non-Faradaic impedance biosensors, which measure electrical property changes without electrochemical reactions, provide simplified operation but have historically suffered from limited sensitivity. This review examines three synergistic strategies that have transformed non-Faradaic sensor performance: micro/nanoparticle-assisted enhancement achieving 10- to 15-fold sensitivity improvements, microfluidic integration for enhanced mass transport, and complementary metal-oxide-semiconductor (CMOS) technology enabling high spatiotemporal resolution through on-chip integration. Recent innovations combining these approaches have achieved femtomolar detection limits for proteins and single bacterial sensitivity, representing a 10- to 100-fold improvement over conventional non-Faradaic methods. We analyze the strengths and limitations of each strategy, their synergistic potential, and emerging directions in material and system integration. This review provides a roadmap for developing advanced non-Faradaic biosensing platforms for healthcare diagnostics, environmental monitoring, and biomedical research.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.